Fox Chase Cancer Center and Temple Health physicians and scientists participated in the presentation and discussion of eight research projects at the American Society of Hematology (ASH) 2024 Annual Meeting, held this past December in San Diego.

The abstracts below, presented at this year's meeting, represent leading investigation from Fox Chase Cancer Center and Temple Health. Research that includes innovative bench science to new approaches for treating multiple myeloma, acute myeloid leukemia, and mantle cell lymphoma—all laying the groundwork for improved disease management with fewer side effects.

2091: “Comparative Analysis of Dexamethasone-Enhanced Pre-Medication in Motixafortide-Induced Hematopoietic Stem Cell Mobilization for Multiple Myeloma: A Retrospective Study”

2214: “Clinical Validation of a Personalized NHL-TME Model System: One-on-One Comparison between Modeled Drug Responses and Patients’ Clinical Responses”

1573: “Epigenetic Adaptation Promotes Cellular Resilience in Senescence-Like AML Cells”

2165: “Effects of Post-Transplant Cyclophosphamide on Outcomes of Allogenic Stem Cell Transplant Are Different Between Older and Younger Adult Patients: A Single Institutional Experience”

1602: “Inosine Monophosphate Dehydrogenase-2 (IMPDH2) as the Potential Novel Therapeutic Target in Mantle Cell Lymphoma (MCL): The Underlying Tyrosine Phosphorylation-Based Activation Mechanism and Translational Implications”

3739: “Disparities in Psychological Distress and Coping Behaviors Amongst Patients with Indolent Hematologic Malignancies”

4120: “Mitochondrial ACSS1 Regulates Oncometabolite 2-Hydroxyglutarate and?De Novo?Pyrimidine Biosynthesis in Lymphoma Cells: Functional Insights and Translational Implications”

5117: “Sex, Race, and Geographic Disparities in Early Age at Onset Hematologic Malignancies”